Smoking and Targeted Therapy: — How It Changes Your Drug Levels

Not necessarily completely, but it can reduce how much of the drug is active in your blood at any given time. Whether that reduction matters in your case depends on which drug you are taking and how much you smoke. NCCN guidance flags this as a clinically meaningful concern for drugs like erlotinib. The safest approach is to disclose your smoking status and let your oncologist tell you what it means for your specific treatment, rather than assuming it is too small to matter.

Drugs that are broken down primarily through the liver enzyme CYP1A2 are the most sensitive. Erlotinib is the most studied and most cited example in NCCN and ASCO guidance. Other targeted agents use different metabolic pathways and are less affected. Your oncologist will know whether your drug falls into the sensitive category. If you want a direct answer, ask: 'Does my targeted therapy go through the CYP1A2 pathway?' — it is a short, answerable question.

Yes, and clinical bodies including ASCO and NCCN support stopping at any point during cancer treatment. Stopping before you start gives your liver enzyme activity time to return toward a non-smoker baseline, which helps the drug reach its intended level from the first dose. If stopping feels difficult right now, tell your team that too. They can refer you to cessation support without judgment — managing nicotine dependence during cancer treatment is something oncology teams see regularly.

For some drugs this is done in practice. With erlotinib, for example, the clinical guidance acknowledges the impact of smoking and dose adjustment is something oncologists consider. But a higher dose is not a straightforward substitution — it can also mean more side effects, and your team has to weigh that carefully. Discussing cessation support is almost always the better first step, rather than assuming a dose adjustment is available as an equivalent alternative.

When you stop smoking, the enzyme activity that tobacco smoke was driving begins to return toward baseline. The drug is cleared more slowly, and blood levels can rise — sometimes by a meaningful amount. This is not dangerous in itself, but it is a change your oncologist needs to know about. Tell your team when you stop, so they can decide whether to monitor you more closely or review your dose. Quitting mid-treatment is always welcome; giving your team a heads-up just allows them to manage the transition well.

We do not yet know definitively. The enzyme-activating compounds in cigarette smoke come largely from combustion products, which e-cigarettes produce in much smaller quantities. However, the evidence on how vaping affects drug metabolism is still immature, and the answer may depend on the specific product and how much you use it. The safest approach is to tell your oncologist exactly what you are using — including vaping — so they can factor it into their thinking rather than assume it has no effect.

For most targeted therapies in routine care, blood drug levels are not routinely monitored the way they are for some other medicines. Your oncologist is working from expected pharmacokinetics — how the drug typically behaves in the body — adjusted for what you tell them. This is why your smoking status is the key input, rather than a blood test that confirms the effect after the fact. If your response to treatment is not what was expected, your team may consider therapeutic drug monitoring depending on which drug you are taking and what your centre can offer.

No. Quitting at any point during treatment is worthwhile. The enzyme changes that smoking causes are not permanent — they begin to reverse when the exposure stops. Quitting mid-treatment means your team will want to know when you stopped, so they can watch for a rise in drug levels and decide whether anything needs adjusting. There is no stage of targeted therapy at which stopping is too late to make a difference — to your drug levels or to your health more broadly.